In the United States for 2014, about 62,900 new thyroid cancer cases will be diagnosed. Medullary thyroid cancer – a rare form of cancer located in the thyroid gland at the base of the throat – represents only about three to four percent of all thyroid cancers. Of those cases, just one third will be locally advanced or metastatic disease. With Thyroid Cancer Awareness Month in full swing, AstraZeneca has launched the aMTCSupport.com online resource center to provide information and support specifically designed for people living with advanced medullary thyroid cancer (aMTC) and their loved ones.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7080731-astrazeneca-amtcsupport-resources-for-advanced-medullary-thyroid-cancer/
International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
In preparation for July 4th and the summer months when instances of food poisoning increase, the Ad Council and the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), are continuing their national Food Safe Families public service campaign, the first multimedia effort designed to raise awareness of the risks of foodborne illness (or food poisoning) in the home.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56338-ad-council-usda-hhs-food-safe-families-public-service-campaign
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Adults over the age of 60 are at the greatest risk of atrial fibrillation (AF), a potentially life-threatening heart rhythm disorder. Yet, according to a recent survey conducted by the Heart Rhythm Society (HRS), more than 25 percent of Americans between the ages of 55 and 64 have never heard of AF. Today marks the kick-off of HRS’ second annual “A-Fib Feels Like” campaign to help educate Americans about the symptoms and warning signs associated with AF and encourage those who suffer from the disorder to talk to their doctors about their risks and potential treatment options.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57735-a-fib-feels-like-campaign-warning-signs-atrial-fibrillation
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
If you are short in magnesium, you may not show any symptoms, you may just ignore them, or you may attribute them to some other nutrient deficiency. However, moderate or severe magnesium deficiency results in malnutrition, loss of appetite, nausea, weakness, personality changes, and arrhythmias.
Two of the most beloved holiday icons are leveraging their celebrity this season to bring attention to heart disease – the No. 1 cause of death in the U.S. Mrs. Claus is inviting American families to join her in making the same, heart-healthy lifestyle changes she and Santa are taking on this year to raise awareness for nutrition’s role in heart health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7183432-heart-healthier-holiday-dsm/
Ever since Donna and John met at work three decades ago, they've had the kind of smooth, comfortable relationship that comes when attraction is accompanied by compatible interests as well as strengths and weaknesses that balance each other. They pictured their senior years as an extension of what Donna Dean calls “this nice, easy life. We didn't see the calamity that was coming.”
Brookdale Senior Living, the nation's largest dementia care provider, has created new resources for care partners as part of National Alzheimer's Awareness Month in November. The candid discussion of many of the disease's most difficult challenges includes an up-close look at Donna's and John’s lives since he developed dementia.
The couple shares on video how following John's diagnosis, they adapted and sustained daily routines, emotional connection and affection. Donna speaks of her uncertainties about how to manage her reactions to behavioral expressions, the adjustment to John's move to a dementia care community and how keeping a journal helped her logistically and emotionally.
To view the multimedia release go to:
http://www.multivu.com/players/English/7722131-brookdale-alzheimers-awareness/
The View’s Elisabeth Hasselbeck hosted the eighth-annual More Magazine | Fitness Magazine Women’s Half-Marathon in Central Park on April 3rd. More and Fitness magazines in partnership with New York Road Runners, welcomed nearly 10,000 runners for the biggest women’s-only half marathon in the country. Hasselbeck also participated in the race, running her first half marathon with her own Team Nogii to raise money for Celiac Disease research, an autoimmune disease from which she suffers. Hasselbeck finished with a time of 1:44:32.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/more-fitnessmagazine/48499/
